Compare JAZZ & GMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | GMED |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.3B |
| IPO Year | 2007 | 2012 |
| Metric | JAZZ | GMED |
|---|---|---|
| Price | $169.65 | $91.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $194.40 | $93.09 |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 358.86 |
| EPS | N/A | ★ 3.08 |
| Revenue | ★ $4,157,832,999.00 | $2,769,804,000.00 |
| Revenue This Year | $6.00 | $16.66 |
| Revenue Next Year | $6.84 | $8.27 |
| P/E Ratio | ★ N/A | $29.58 |
| Revenue Growth | 4.14 | ★ 11.75 |
| 52 Week Low | $95.49 | $51.79 |
| 52 Week High | $182.99 | $94.93 |
| Indicator | JAZZ | GMED |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 72.86 |
| Support Level | $164.44 | $87.20 |
| Resistance Level | $182.75 | $90.26 |
| Average True Range (ATR) | 5.88 | 2.31 |
| MACD | -1.21 | -0.47 |
| Stochastic Oscillator | 34.58 | 87.03 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.